KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Debt to Equity (2017 - 2020)

Historic Debt to Equity for Xenon Pharmaceuticals (XENE) over the last 4 years, with Q1 2020 value amounting to $0.17.

  • Xenon Pharmaceuticals' Debt to Equity rose 170.07% to $0.17 in Q1 2020 from the same period last year, while for Mar 2020 it was $0.17, marking a year-over-year increase of 170.07%. This contributed to the annual value of $0.17 for FY2019, which is N/A changed from last year.
  • As of Q1 2020, Xenon Pharmaceuticals' Debt to Equity stood at $0.17, which was up 170.07% from $0.17 recorded in Q4 2019.
  • Xenon Pharmaceuticals' Debt to Equity's 5-year high stood at $0.24 during Q1 2018, with a 5-year trough of $0.13 in Q3 2018.
  • Moreover, its 4-year median value for Debt to Equity was $0.18 (2019), whereas its average is $0.19.
  • Within the past 5 years, the most significant YoY rise in Xenon Pharmaceuticals' Debt to Equity was 5424.21% (2019), while the steepest drop was 3203.07% (2019).
  • Quarter analysis of 4 years shows Xenon Pharmaceuticals' Debt to Equity stood at $0.19 in 2017, then decreased by 29.27% to $0.13 in 2018, then grew by 26.15% to $0.17 in 2019, then dropped by 1.28% to $0.17 in 2020.
  • Its Debt to Equity stands at $0.17 for Q1 2020, versus $0.17 for Q4 2019 and $0.21 for Q3 2019.